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Objective: Low-dose add-back therapy during postoperative GnRH agonist treatment could lower the
risk of add-back-induced endometriosis recurrence and reduce treatment dropout compared with a
regular dose. However, the effect of low-dose add-back therapy is still unknown. The aim of this study
was to determine whether low-dose add-back therapy can also effectively relieve the hypoestrogenic
side effects and simultaneously maintain a therapeutic response of GnRH agonist treatment.
Materials and methods: This analysis was a prospective cohort study. During postoperative GnRH agonist
treatment, a total of 107 women were prescribed add-back therapy [oral combination tablet; estradiol
valerate (1mg) andmedroxyprogesterone acetate (2.5mg)] (Indivina; Orion, Espoo, Finland) for 20weeks.
Patients in the low dose add-back therapy groupwere prescribed the tablet once a day, and patients in the
regular dose group were given the tablet twice a day. Hypoestrogenic side effects, such as hot ﬂashes and
insomnia, were recorded. Patients were also questioned regarding their pelvic symptoms and pain to
evaluate the possibility of endometriosis recurrence. Lumbar spine (L2eL4) bone mineral density was
measured using dual X-ray absorptiometry. The dropout rates in both groups were also evaluated.
Results: The incidence of hypoestrogenic side effects was lower in the low dose group compared with the
regular dose group, including hot ﬂashes (19.2% vs. 21.8%, p ¼ 0.741) and insomnia (15.4% vs. 18.2%,
p ¼ 0.699), although there were no signiﬁcant difference between the groups. In addition, a higher
number of patients in the regular dose group dropped out of treatment compared to the low dose group
(14.5% and 9.6%, respectively, p ¼ 0.435). The patients in both groups had a signiﬁcant loss of mean bone
mineral density during therapy (p < 0.001 and p ¼ 0.018 for the low dose and regular dose groups,
respectively).
Conclusion: Low dose add-back therapy could effectively ameliorate hypoestrogenic side effects and
simultaneously maintain the therapeutic response of GnRH agonist treatment. The treatment dropout
was lower compared with a regular dose. Therefore, low dose add-back therapy can be considered a
treatment choice during postoperative GnRH agonist treatment.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).ics and Gynecology, Taipei
ad, Taipei 112, Taiwan.
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Endometriosis is a complex disease because of the signiﬁcant
diversity of clinical presentations and complicated treatment op-
tions [1,2]. Surgical intervention followed by medical treatment to
prevent endometriosis recurrence has been used as a standard
treatment for this complex disorder [3]. Postoperative medical
treatment with a GnRH agonist can effectively prevent recurrence,y Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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as hot ﬂashes, insomnia, and osteoporosis [4,5]. Therefore, to
relieve the hypoestrogenic side effects and reduce treatment
dropout, add-back therapy, with lowest effective hormone support,
plays an important role in postoperative GnRH agonist treatment.
Add-back therapy provides an alternative for patients who are
responsive to GnRH agonist treatment but experience unwanted
hypoestrogenic side effects. The rationale for this approach derives
from the estrogen threshold hypothesis proposed by Barbieri [6],
which allows for patients with endometriosis to replace estrogen in
a titrated fashion, preventing hypoestrogenic side effects without
stimulating this estrogen-sensitive disease. However, how to titrate
the optimal dosage, the lowest effective dose of add-back therapy,
is the most critical point of excellent add-back therapy. High-dose
add-back therapy might be effective in reducing hot ﬂashes,
insomnia, and osteoporosis, but simultaneously, in this estrogen-
sensitive disease, it might lead to problems of pelvic pain, endo-
metriosis recurrence, and treatment dropout [7]. Therefore, deter-
mining the lowest effective dose of add-back therapy continues to
be investigated.
Previous studies have revealed the effects of different add-back
regimens, including daily oral norethindrone acetate (5mg) or daily
norethindrone acetate (5 mg) in conjunctionwith different doses of
conjugated equine estrogens (0.625 or 1.25 mg) or estradiol (2 mg)
only [8e13]. Although hypoestrogenic symptoms are relieved by
add-back therapy, patient compliance is still a problem because of
add-back-induced endometriosis recurrence. Because the aim of
add-back therapy is to relieve hypoestrogenic side effects, and not
to interfere with the GnRH agonist treatment, ﬁnding out the
lowest effective dose of add-back therapy is necessary. Therefore,
we conducted a cohort study on women who received post-
operative GnRH agonist treatment with add-back therapy. We tried
to lower the regular dose of add-back therapy to determine
whether low-dose add-back therapy can also effectively relieve
hypoestrogenic side effects and simultaneously maintain a thera-
peutic response of GnRH agonist treatment.
Materials and methods
This analysis was a prospective cohort study over a 24-week
treatment period and 12-week follow-up period. The study was
conducted at Taipei Veterans General Hospital, Taipei, Taiwan, and
approved by the ethics committee and institutional review board of
the institution. From January 2009 to January 2010, a consecutive
series of 120 patients with a history of symptomatic endometriosis,
which was diagnosed surgically according to the revised American
Society for Reproductive Medicine classiﬁcation, agreed to partici-
pate in the study [14]. No patient received any other hormonal or
medical therapies prior to study entry. In addition, all participants
underwent complete resection of the endometriotic lesions by
laparoscopic surgery and initiation of postoperative GnRH agonist
adjuvant treatment during the next menstruation. All patients
provided written informed consent prior to inclusion in the study.
Once patients were enrolled, allocation of treatment was carried
out according to a patient-centered, partially randomized design;
we allowed women with a preference for a particular treatment to
undergo that treatment, whereas those without a preference were
randomly allocated to either one of the treatment arms. Random-
ization was achieved by opening sequentially numbered, sealed,
opaque envelops that were prepared by using a computer-
generated random number list. Patients in both groups were to
receive a depot preparation of the GnRH agonist leuprolide acetate
(3.75 mg) intramuscularly every 4 weeks plus either an oral com-
bination of 1 mg/2.5 mg tablet (estradiol valerate, 1 mg; medrox-
yprogesterone acetate, 2.5 mg) (Indivina; Orion, Espoo, Finland)once a day or twice a day, beginning with the second GnRH agonist
injection, for 20 weeks. To maintain a more stable therapeutic drug
concentration, we prescribed the therapy twice daily instead of
once daily.
At the pretreatment assessment, the patients were questioned
regarding their pelvic symptoms (dysmenorrhea, nonmenstrual
pelvic pain, and deep dyspareunia), and a pelvic examination was
performed with speciﬁc attention to pelvic tenderness and indu-
ration. The ﬁndings were quantiﬁed according to a modiﬁcation of
the Biberoglu and Behrman scale and rated from 1 to 4 (1¼ no pain,
2 ¼ mild pain, 3 ¼ moderate pain, 4 ¼ severe pain) by the exam-
ining clinician and coordinator using the symptom diaries of the
patients [15]. The scores for three symptoms and two physical signs
were summed to yield a total subjective score. In addition, the same
pelvic symptoms were assessed after the treatment period. The
assessors were blinded to the patient's group allocation.
Bone mineral density (BMD) of the lumbar spine (L2eL4) was
measured using dual X-ray absorptiometry after the initial lapa-
roscopic surgery, before the ﬁrst GnRH agonist was given, and at
the completion of 24 weeks of treatment. All measurements were
performed using the same machine (Hologic Quantitative Digital;
Hologic MDM, Waltham, MA, USA) according to standardized
procedures. The results are expressed as grams per square
centimeter.
At each visit, the patients were questioned directly regarding
the presence or absence of physiologic side effects, such as hot
ﬂashes and insomnia. The participants were requested to complete
a daily diary, to record the frequency of hot ﬂashes and to take part
in a self-administered questionnaire survey based on the Insomnia
Severity Index to assess insomnia symptoms [16,17]. The Insomnia
Severity Index is a valid and reliable self-administered instrument
that measures the perception of current insomnia symptoms. In
addition, participants were questioned indirectly regarding the
presence of other side effects. Physical examinations were per-
formed prior to the treatment and every 4 weeks up to Week 24.
Serum E2 concentrations weremeasured on Day 3 of the menstrual
cycle immediately prior to the initiation of treatment and at
24 weeks. Serum CA 125 was measured simultaneously. Additional
fasting serum samples were obtained to assess circulating total
cholesterol, cholesterol subfractions, and triglyceride levels.
For the endometriosis response, BMD, endocrine effects, and
subjective side effects, we used the ManneWhitney U test, an un-
paired Student t test, or a chi-square test to compare the between-
group differences at baseline and after treatment. The Wilcoxon
matched-pairs signed-rank test or a paired Student t test was used
to compare the within-group differences. Statistical signiﬁcance
was deﬁned as p < 0.05.
Results
Of the 120 patients who were assessed for eligibility, 13 patients
were excluded. Seven patients did not complete the questionnaire,
and six patients did not come to the follow-up visit. Consequently, a
total of 107 women were enrolled in our study. Overall, 52 women
were allocated to receive a low dose of add-back therapy, and 55
women were assigned to receive a regular dose of add-back ther-
apy. There were no signiﬁcant differences between the two groups
in terms of age, parity, body mass index, stage of endometriosis,
pelvic pain scores, and CA 125 levels (Table 1).
The median changes in the overall pelvic pain scores and CA 125
levels from the pretreatment baseline to the completion of GnRH
agonist treatment for the two groups are shown in Table 2. De-
creases in pelvic symptom scores from baseline were statistically
signiﬁcant throughWeek 24 of follow-up for both the low-dose and




group (n ¼ 52)
Regular-dose
group (n ¼ 55)
p
Age (y) 35.8 ± 6.5 36.1 ± 8.3 0.834
Body mass index (kg/m2) 22.1 ± 4.0 21.8 ± 4.6 0.874
Parity, n (%) 0.988
Nulliparous 36 (69.2%) 38 (69.1%)
Parous 16 (30.8%) 17 (30.9%)
Stage of endometriosis, n (%) 0.268
Stage III 32 (61.5%) 28 (50.9%)
Stage IV 20 (38.5%) 27 (49.1%)
CA 125 (U/mL), preoperative 55.9 ± 45.0 59.9 ± 42.1 0.688
Bone mineral density (gm/cm2) 1.075 ± 0.139 1.095 ± 0.116 0.533
Baseline pelvic score 6.7 ± 1.6 7.3 ± 1.8 0.188
The data are the mean ± standard deviation or case numbers.
*p < 0.05, statistically signiﬁcant.
Figure 1. Incidence of hypoestrogenic side effects in both groups after 6 months of
add-back therapy.
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period after completion of therapy. In addition, decreases in CA 125
levels were statistically signiﬁcant in both groups (p < 0.001 and
p < 0.001, respectively). However, there were no signiﬁcant differ-
ences between the groups.
The hypoestrogenic side effects that were induced by the GnRH
agonist, such as hot ﬂashes and insomnia, were evaluated in both
groups after the 6-month add-back therapy (Figure 1). The inci-
dence of hot ﬂashes was 19.2% and 21.8% in the low-dose and
regular-dose groups, respectively (p ¼ 0.741). The incidence of
insomnia was 15.4% and 18.2% in the low-dose and regular-dose
groups, respectively (p ¼ 0.699). The incidence of hypoestrogenic
side effects was higher in the regular-dose group, but no signiﬁcant
difference was found between the groups. In addition, a higher
number of patients who received the regular dose of add-back
therapy dropped out compared to those who received the low
dose (14.5% and 9.6%, respectively, p ¼ 0.435), but there was no
signiﬁcant difference. The causes for dropout from the study were
lack of symptom improvement, adverse events such as emotional
change, hot ﬂashes, and noncompliance.
The results of the analysis of total cholesterol levels, circulating
cholesterol subfractions, triglycerides, and glucose during the
follow-up period are listed in Table 2. There were no signiﬁcant
differences in the mean changes from baseline for any of these
parameters between the groups (Table 3).
The mean changes in lumbar spine BMD from baseline and at
the end of 24 weeks of therapy for patients with follow-up data are
shown in Figure 2. During GnRH agonist therapy, the patients all
had a progressive and signiﬁcant loss of mean BMD during therapy
(p < 0.001 and p ¼ 0.018 for the low-dose and regular-dose groups,
respectively). However, the low-dose therapy was not as effectiveTable 2
Hormone and metabolic parameters of both groups before and after 24 weeks of treatm
Variable Low-dose group (n ¼ 52)
Before After p
Pelvic score 6.7 (1.6) 3.2 (1.1) <
CA 125 (U/mL) 55.9 (45.0) 9.5 (5.2) <
E2 (pg/mL) 43.1 (27.4) 24.8 (14.6)
Total CHO (mg/dL) 163.4 (36.2) 166.9 (28.7)
HDL (mg/dL) 55.7 (11.4) 59.5 (13.5)
LDL (mg/dL) 95.1 (32.6) 99.2 (28.4)
TG (mg/dL) 65.4 (25.5) 69.8 (46.3)
CHO/HDL ratio 3.0 (0.8) 3.1 (1.0)
Glucose (mg/dL) 86.5 (12.6) 89.5 (9.2)
The values are expressed as the mean (±standard deviation).
*p < 0.05, statistically signiﬁcant.
HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; TG ¼ triglycerides; Totaas the regular-dose therapy. Fortunately, according to previous
studies, the deterioration effect on BMD is transient.Discussion
In our study, we found that low-dose add-back therapy can
ameliorate hypoestrogenic side effects similar to a regular dose and
simultaneously avoid the risk of recurrent pelvic pain and treat-
ment dropout while maintaining the GnRH agonist effect. There-
fore, low-dose add-back therapy can be considered a treatment
choice during postoperative GnRH agonist treatment.
The beneﬁts of GnRH agonist treatment in managing the pelvic
symptoms of endometriosis and preventing its recurrence are well
established [1]. Therefore, an important issue regarding treatment
with a GnRH agonist is how to effectively reduce the intolerable
side effects and make patients comfortable without inducing
recurrent pelvic pain. A series of therapeutic trials have reported
the effectiveness and safety of add-back therapy, but the dosage
was higher; the chance to induce recurrent pelvic pain was higher,
too. Fernandez et al [9] demonstrated that estradiol (2 mg) plus
promegestone (0.5 mg) per day as add-back therapy could effec-
tively reduce the side effects of endometriosis symptoms without a
deleterious change in lipid parameters. In addition, Surrey and
Hornstein [8] also reported a relatively higher add-back dosage
with conjugated equine estrogens (1.25 mg) and norethindroneent.
Regular-dose group (n ¼ 55)
Before After p
0.001* 7.3 (1.8) 3.7 (1.1) <0.001*
0.001* 59.9 (42.1) 12.9 (8.9) <0.001*
0.001* 38.1 (24.7) 26.6 (14.4) 0.021*
0.303 172.2 (38.6) 173.7 (41.3) 0.659
0.051 52.1 (14.3) 57.2(18.7) 0.111
0.083 107.7 (30.7) 107.1 (28.3) 0.893
0.543 70.8 (27.4) 69.1 (43.4) 0.873
0.381 3.0 (0.6) 2.9 (0.7) 0.127
0.240 100.6 (11.9) 101.8 (13.6) 0.410
l CHO ¼ total cholesterol.
Table 3






Pelvic score 3.4 ± 0.2 3.4 ± 0.3 0.884
CA 125 (U/mL) 46.3 ± 6.9 47.0 ± 6.9 0.944
E2 (pg/mL) 18.3 ± 4.7 11.5 ± 4.5 0.317
Total cholesterol (mg/dL) 3.4 ± 3.3 1.2 ± 2.7 0.622
HDL (mg/dL) 5.4 ± 2.6 2.7 ± 2.2 0.464
LDL (mg/dL) 4.1 ± 2.3 0.6 ± 4.3 0.304
TG (mg/dL) 4.4 ± 7.1 1.3 ± 7.6 0.628
Cholesterol/HDL ratio 0.1 ± 0.1 0.1 ± 0.1 0.120
Glucose (mg/dL) 3.0 ± 2.3 1.2 ± 1.4 0.539
The values are expressed as the mean ± standard error.
*p < 0.05, statistically signiﬁcant.
HDL ¼ high-density lipoprotein; LDL ¼ low-density lipoprotein; TG ¼ triglycerides.
Figure 2. Mean changes in bone mineral density in both groups. *Comparison be-
tween pretherapy and end of 24 weeks of therapy for each group (p < 0.05).
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prospective, multicenter, randomized, double-blinded clinical trial
reported a higher number of dropouts for persistent and recurrent
pelvic pain among those patients who received higher estrogen
doses, which was expected [7]. Thus, in our study, we proposed a
low dose add-back with estradiol valerate (1 mg) and medrox-
yprogesterone acetate (2.5 mg) and succeeded in reducing the
hypoestrogenic side effects and ameliorating vasomotor symptoms.
In addition, the low dose resulted in a reduced occurrence of pa-
tients who dropped out because of persistent or recurrent pelvic
pain. Therefore, to ameliorate bothersome side effects andmaintain
compliance with GnRH agonist treatment, low-dose add-back
therapy might be a better and more effective choice than higher
doses of therapy.
Regarding the bothersome vasomotor symptoms that are asso-
ciated with GnRH agonist treatment, estrogen-containing add-back
therapy might be a better option than progestin-alone add-back
therapy [2,10,18,19]. Progestogen therapy in the form of medrox-
yprogesterone acetate or norethindrone in combinationwith GnRH
agonist has been evaluated in several small studies. Cedars and
colleagues [20] reported no decrease in pain or resolution of
endometriotic implants when medroxyprogesterone acetate was
used as an add-back at doses of 20e30 mg/d. Riis and colleagues
[21] successfully used lower daily doses of norethindrone tominimize bone loss, but they did not assess pain, extent of disease,
or vasomotor symptoms. However, the continuous administration
of medroxyprogesterone acetate appears to reverse the beneﬁcial
effects of GnRH agonist; moreover, norethindrone has adverse ef-
fects on lipid proﬁles [22]. Vasomotor symptoms, hot ﬂashes, and
vaginal dryness are all bothersome side effects and are directly
related to the rapid drop in estrogen levels [23,24]. Therefore,
estrogen-containing add-back therapy might be more appropriate
and effective in reducing vasomotor symptoms than progestin-
alone therapy and would maintain compliance and the beneﬁts of
GnRH agonist treatment.
The loss of BMD is another important issue in the treatment of
endometriosis. Several investigators have demonstrated that after a
trend toward normalization was noted, BMD had not returned to
baseline by 6 or 12 months after completion of treatment without
add-back therapy [25]. Previous study suggested that for bone
protection, a GnRH agonist should be administered to patients with
endometriosis in addition to an appropriate add-back therapy [10].
Additionally, Pierce et al [3] observed that only a small reduction of
bone loss occurred with add-back therapy. Our study of add-back
therapy revealed that BMD was reduced but remained within the
normal range. The difference in BMD loss between the two dosages
was not statistically signiﬁcant; therefore, regarding BMD loss and
failure of recovery, we suggest that a GnRH agonist should not be
administered in the absence of an appropriate add-back therapy.
A limitation of the current study was the short course of treat-
ment and follow-up period. Higher doses of add-back have been
used primarily for the treatment of endometriosis in conjunction
with a GnRH agonist for up to 12 months in an effort to completely
eliminate BMD loss, which might not be the goal for a short course
of treatment. Thus, it is difﬁcult to compare outcomes from a 12-
month study using higher doses of agents to a 6-month trial.
Therefore, there is no evidence to suggest that the add-back used in
this study can be safely used for more than 6 months. In addition,
we did not record the severity of hot ﬂashes, which is another
important issue to assess hypoestrogenic symptoms. This lack of
quantiﬁcation is a signiﬁcant problem.
In conclusion, in our study, low-dose add-back therapy could
effectively ameliorate hypoestrogenic side effects and simulta-
neously maintain the therapeutic response of GnRH agonist treat-
ment without recurrent pelvic pain and treatment dropout.
Therefore, low-dose add-back therapy can be considered a treat-
ment choice during postoperative GnRH agonist treatment. Large,
prospective, randomized controlled studies need to be conducted
in the future to conﬁrm our preliminary results.Conﬂict of interest
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